Company intelligence / Profile preview
Vichem Chemie Research
Budapest, Hungaryvichemchemie.com ↗
- Ownership
- Private
- Employees
- ~25
- Development stage
- Preclinical
01
Overview
Vichem Chemie Research has a pipeline of small molecule drug candidates targeting kinases and other proteins relevant to cancer and infectious diseases. Their lead program, VS2‑370 targeting CDK9 for neoplasms, is in Phase 1. Other programs are in preclinical development for multiple myeloma, tuberculosis, and acute myeloid leukemia.
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- Small molecule
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Vichem Chemie Research.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Vichem Chemie Research.